The Supreme Court's refusal to make Nucleic Acid Testing compulsory for blood transfusions raises important questions about the limits of judicial policymaking in technical domains. Critically analyse the ruling in the context of the right to health and separation of powers.

Q. The Supreme Court's refusal to make Nucleic Acid Testing compulsory for blood transfusions raises important questions about the limits of judicial policymaking in technical domains. Critically analyse the ruling in the context of the right to health and separation of powers. (15 marks, 250-350 words)

Human blood is a "drug" under the Drugs and Cosmetics Act, 1940, making transfusion safety a regulatory question, not merely a clinical one [4]. The Supreme Court's March 2026 refusal to mandate Nucleic Acid Testing (NAT) is defensible on institutional-competence grounds, yet it leaves the Article 21 promise of safe blood dependent on executive will.

The ruling and its reasoning - A Bench headed by CJI Surya Kant declined the plea, holding that judges lack specialised knowledge of medical science and of the costs involved, and that States face fiscal constraints [1]. - The petitioner NGO was given liberty to move State Health Secretaries, respecting health as a State List subject (Entry 6, List II) [1].

Why restraint is justified - Mandating NAT is a polycentric fiscal choice — money spent on costlier molecular testing competes with expanding blood-bank coverage itself. - Designated expert fora exist: the NBTC, the apex policy body under NACO, which supports a national network of blood centres and frames screening protocols [3]. - Globally, the WHO minimum standard is quality-assured screening of all donations for HIV, HBV, HCV and syphilis, not universal NAT [2] — courts pre-empting this calibration risks unscientific uniformity.

Where the ruling falls short - Right to health under Article 21 (Paschim Banga Khet Mazdoor Samity) implies not just available blood but safe blood; antibody-based ELISA misses infections in the window period. - Thalassemia patients, transfused every few weeks lifelong, face cumulative exposure — a rights question, not only a budgetary one. - Deferring to States alone risks fragmenting a national safety floor.

Judicial restraint here is constitutionally sound but must not become regulatory silence. The executive route is the correct one: an NBTC-led cost-effectiveness review, hub-and-spoke centralised NAT to avoid equipping every blood centre, and phased priority for transfusion-dependent patients. Separation of powers is vindicated only when the political branches discharge the duty the Court declined to assume.

(~320 words)

Sources: 1. Supreme Court of India — order dated 14 March 2026, plea seeking mandatory NAT in blood banks (Sarvesham Mangalam Foundation) — the Court's refusal, its institutional-competence reasoning, and liberty to approach State Health Secretaries 2. WHO, Blood safety and availability (fact sheet) — mandatory quality-assured screening for HIV, HBV, HCV and syphilis as the global minimum standard 3. NACO, Blood Transfusion Services / National Blood Transfusion Council — NBTC as apex policy body and the national blood-centre network 4. CDSCO, Blood Products — regulatory requirements for blood banks — blood regulated as a drug under the Drugs and Cosmetics Act, 1940